Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Porphysome Mediated Drug Delivery and PET Imaging to Enhance Adoptive Double Negative T-cell Therapy for Non-Small Cell Lung Cancer Treatment

FY 2016-17

Summary
Since the leading cause of cancer death worldwide is lung cancer and its 5 year survival rate is <20% adjuvant treatments are needed. Immunotherapy is promising because it can improve patient survival. However, to improve immunotherapy, we need to understand where immune cells migrate to and overcome immune cell deterioration. To address these issues, we propose the use of nanoparticles, called porphysomes. Our lab has shown that: 1) porphysomes can be attached to radioisotopes and then used in imaging, and 2) porphysomes can carry and locally deliver drugs to tumors to reduce systemic drug toxicity. This project will combine these aspects of porphysomes to address the problems associated with one form of immunotherapy, called adoptive cell therapy (ACT), for the treatment of lung cancer. In ACT, immune cells are removed from humans, grown ex vivo, and injected into patients, for targeting and killing of tumor cells. Firstly, we will track the migration of immune cells in a lung cancer mouse model, by radiolabeling porphysomes and then attaching porphysomes to an immune cell called the double negative T-cell (DNT). DNTs from a healthy donor do not attack normal cells of the recipient, and are safer. Porphysome conjugated DNTs will be imaged via positron emission tomography. Next, we will load porphysomes with an "immune booster" and attach porphysomes to DNTs. The immune booster will be slowly released from the porphysomes, and be locally delivered to the DNTs. This continual stimulation of DNTs will improve their killing ability. Results will firstly, improve our understanding of the localization of immune cells during ACT and enable us to optimize parameters to improve its efficacy. Secondly, porphysome-mediated local delivery of an immune booster should prevent immune cell deterioration and systemic toxicity. Successful proof-of-concept will allow for loading other immune regulating agents into nanoparticles and improve immunotherapy for other cancers.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
362492
Name
Lou Jenny
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Porphysome Mediated Drug Delivery and PET Imaging to Enhance Adoptive Double Negative T-cell Therapy for Non-Small Cell Lung Cancer Treatment
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Immunotherapy; Nanoparticles
Abstract
Since the leading cause of cancer death worldwide is lung cancer and its 5 year survival rate is <20% adjuvant treatments are needed. Immunotherapy is promising because it can improve patient survival. However, to improve immunotherapy, we need to understand where immune cells migrate to and overcome immune cell deterioration. To address these issues, we propose the use of nanoparticles, called porphysomes. Our lab has shown that: 1) porphysomes can be attached to radioisotopes and then used in imaging, and 2) porphysomes can carry and locally deliver drugs to tumors to reduce systemic drug toxicity. This project will combine these aspects of porphysomes to address the problems associated with one form of immunotherapy, called adoptive cell therapy (ACT), for the treatment of lung cancer. In ACT, immune cells are removed from humans, grown ex vivo, and injected into patients, for targeting and killing of tumor cells. Firstly, we will track the migration of immune cells in a lung cancer mouse model, by radiolabeling porphysomes and then attaching porphysomes to an immune cell called the double negative T-cell (DNT). DNTs from a healthy donor do not attack normal cells of the recipient, and are safer. Porphysome conjugated DNTs will be imaged via positron emission tomography. Next, we will load porphysomes with an "immune booster" and attach porphysomes to DNTs. The immune booster will be slowly released from the porphysomes, and be locally delivered to the DNTs. This continual stimulation of DNTs will improve their killing ability. Results will firstly, improve our understanding of the localization of immune cells during ACT and enable us to optimize parameters to improve its efficacy. Secondly, porphysome-mediated local delivery of an immune booster should prevent immune cell deterioration and systemic toxicity. Successful proof-of-concept will allow for loading other immune regulating agents into nanoparticles and improve immunotherapy for other cancers.
Competitiondate
201611
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lou, Jenny
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2016-17) | Canada Spends